Growth in the cost of imported drugs to be restrained 

Growth in the cost of imported drugs will be restrained. This is due to the change in the formula for calculating the purchase price. One term is excluded from it — the exchange difference between the contract value, determined on the basis of the Central Bank rate at the date of conclusion of the contract and the date of filling the CCD (cargo customs declaration), Norma reports.

Thus, the purchase price of imported drugs or medical products form the contract price at the CB rate on the date of filling the CCD, customs payments and other expenses in accordance with clauses 1.1 and 1.2 of the Provision on composition of costs for the production and sale of products (works, services) and formation of financial results.

The purchase price is the basis for determining the final selling price. A marginal surcharge is applied to it (no more than 15%) and a wholesale price is formed, to which a retail surcharge is then applied (no more than 20%). This forms the final price on the pharmacy counter. 

Goods under the import contract must be brought and issued in the mode “release for free circulation” within 180 days from the date of payment. At the same time, the rate of foreign currencies in relation to the national one is steadily growing. For example, the US dollar over the past 180 days has risen in price by 238.49 soums. That is, the inclusion of exchange differences in the purchase price leads to an additional increase in the final price and affects the consumer's pocket. 

Accordingly, exclusion of this component will allow a little to restrain the rise in prices for imported drugs and medical products.